Enanta Pharmaceuticals (ENTA) News Today $5.81 +0.06 (+1.04%) Closing price 05/23/2025 04:00 PM EasternExtended Trading$5.80 -0.01 (-0.17%) As of 05/23/2025 07:07 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock ENTA Latest News All Sources Trusted Sources MarketBeat Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 Time Period Enanta Pharmaceuticals, Inc.: Enanta Pharmaceuticals Announces Data from its Phase 2 Study of Zelicapavir in Children with Respiratory Syncytial Virus to be Presented at the ...May 24 at 6:48 PM | finanznachrichten.deD. E. Shaw & Co. Inc. Has $2.42 Million Stake in Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA)D. E. Shaw & Co. Inc. reduced its holdings in Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA - Free Report) by 15.9% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 421,594 shares of the biotechnology companMay 23 at 3:35 AM | marketbeat.com331,900 Shares in Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Acquired by Stonepine Capital Management LLCStonepine Capital Management LLC purchased a new position in shares of Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA - Free Report) during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm purchased 331,900 shares of the bioMay 20, 2025 | marketbeat.comJacobs Levy Equity Management Inc. Acquires 98,285 Shares of Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA)Jacobs Levy Equity Management Inc. grew its holdings in shares of Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA - Free Report) by 51.3% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 290,011 shares ofMay 19, 2025 | marketbeat.comDimensional Fund Advisors LP Increases Stock Position in Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA)Dimensional Fund Advisors LP boosted its holdings in shares of Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA - Free Report) by 52.8% during the 4th quarter, according to its most recent 13F filing with the SEC. The fund owned 297,106 shares of the biotechnology company's stock after purchasing an additMay 17, 2025 | marketbeat.comEnanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Just Reported Second-Quarter Earnings: Have Analysts Changed Their Mind On The Stock?May 15, 2025 | uk.finance.yahoo.comEnanta Pharmaceuticals (NASDAQ:ENTA) Issues Quarterly Earnings ResultsEnanta Pharmaceuticals (NASDAQ:ENTA - Get Free Report) announced its earnings results on Monday. The biotechnology company reported ($1.06) earnings per share for the quarter, beating the consensus estimate of ($1.16) by $0.10. Enanta Pharmaceuticals had a negative return on equity of 75.53% and a negative net margin of 157.57%.May 14, 2025 | marketbeat.comEnanta Pharmaceuticals, Inc. (ENTA): The Best Breakout Stock to Buy According to AnalystsMay 5, 2025 | insidermonkey.com1,038,000 Shares in Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Purchased by RA Capital Management L.P.RA Capital Management L.P. acquired a new stake in Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA - Free Report) during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor acquired 1,038,000 shares of the biotMay 3, 2025 | marketbeat.comEnanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Shares Sold by Caligan Partners LPCaligan Partners LP lowered its stake in shares of Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA - Free Report) by 42.7% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 184,826 shares of the biotechnology companMay 3, 2025 | marketbeat.comBoothbay Fund Management LLC Has $492,000 Stock Position in Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA)Boothbay Fund Management LLC lessened its holdings in Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA - Free Report) by 42.7% during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 85,649 shares of the biotechnology company's stocMay 3, 2025 | marketbeat.comEnanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Given Consensus Rating of "Moderate Buy" by AnalystsEnanta Pharmaceuticals, Inc. (NASDAQ:ENTA - Get Free Report) has received an average rating of "Moderate Buy" from the five research firms that are presently covering the company, Marketbeat.com reports. One analyst has rated the stock with a sell recommendation, three have given a buy recommendatMay 2, 2025 | marketbeat.comEnanta Pharmaceuticals (ENTA) to Release Quarterly Earnings on MondayEnanta Pharmaceuticals (NASDAQ:ENTA) will be releasing its Q2 2025 earnings before the market opens on Monday, May 5. (View Earnings Report at https://www.marketbeat.com/earnings/reports/2025-5-5-enanta-pharmaceuticals-inc-stock/)April 30, 2025 | marketbeat.comJPMorgan Chase & Co. Has $938,000 Stock Position in Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA)JPMorgan Chase & Co. reduced its position in Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA - Free Report) by 33.0% in the 4th quarter, according to its most recent filing with the SEC. The firm owned 163,113 shares of the biotechnology company's stock after selling 80,515 shares during the period. JPMoApril 30, 2025 | marketbeat.comMarshall Wace LLP Increases Stake in Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA)Marshall Wace LLP increased its position in shares of Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA - Free Report) by 9.3% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 930,087 shares of the biotechnology company'sApril 26, 2025 | marketbeat.comFederated Hermes Inc. Trims Stock Holdings in Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA)Federated Hermes Inc. lessened its stake in shares of Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA - Free Report) by 90.3% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 8,534 shares of the biotechnologyApril 21, 2025 | marketbeat.comTrexquant Investment LP Acquires 67,040 Shares of Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA)Trexquant Investment LP boosted its stake in shares of Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA - Free Report) by 97.3% during the 4th quarter, according to its most recent 13F filing with the SEC. The firm owned 135,954 shares of the biotechnology company's stock after buying an additional 67,040April 14, 2025 | marketbeat.comPrudential Financial Inc. Lowers Stake in Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA)Prudential Financial Inc. trimmed its stake in Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA - Free Report) by 61.6% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 60,364 shares of the biotechnology company's stocApril 13, 2025 | marketbeat.comEnanta Pharmaceuticals Announces Respiratory Syncytial Virus Data Presentation at ESCMID Global 2025April 8, 2025 | businesswire.comEnanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Receives Average Recommendation of "Moderate Buy" from BrokeragesShares of Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA - Get Free Report) have received a consensus rating of "Moderate Buy" from the five ratings firms that are currently covering the company, MarketBeat.com reports. One equities research analyst has rated the stock with a sell rating, three have asApril 6, 2025 | marketbeat.comEnanta Pharmaceuticals at H.C. Wainwright: Strategic Shift to ImmunologyMarch 29, 2025 | investing.comEnanta Pharmaceuticals (NASDAQ:ENTA) Stock Price Passes Below Two Hundred Day Moving Average - Here's What HappenedEnanta Pharmaceuticals (NASDAQ:ENTA) Shares Pass Below Two Hundred Day Moving Average - Here's What HappenedMarch 26, 2025 | marketbeat.comShort Interest in Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Decreases By 27.2%Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA - Get Free Report) was the recipient of a large decline in short interest in February. As of February 28th, there was short interest totalling 2,600,000 shares, a decline of 27.2% from the February 13th total of 3,570,000 shares. Based on an average daily volume of 562,300 shares, the days-to-cover ratio is currently 4.6 days. Approximately 13.1% of the shares of the company are short sold.March 17, 2025 | marketbeat.comEnanta Pharmaceuticals to Present at the H.C. Wainwright 3rd Annual Autoimmune & Inflammatory Disease Virtual ConferenceMarch 17, 2025 | businesswire.comEnanta Pharmaceuticals to Present Data for its Respiratory Syncytial Virus Program at the 13th International RSV SymposiumMarch 12, 2025 | finance.yahoo.comEnanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Given Average Recommendation of "Moderate Buy" by BrokeragesEnanta Pharmaceuticals, Inc. (NASDAQ:ENTA - Get Free Report) has been assigned an average rating of "Moderate Buy" from the five ratings firms that are currently covering the company, MarketBeat Ratings reports. One research analyst has rated the stock with a sell rating, three have given a buy raMarch 11, 2025 | marketbeat.comEnanta Pharmaceuticals (NASDAQ:ENTA) Stock Crosses Below 200 Day Moving Average - Should You Sell?Enanta Pharmaceuticals (NASDAQ:ENTA) Shares Cross Below Two Hundred Day Moving Average - What's Next?March 7, 2025 | marketbeat.comEnanta Pharmaceuticals (NASDAQ:ENTA) Share Price Passes Below Two Hundred Day Moving Average - Time to Sell?Enanta Pharmaceuticals (NASDAQ:ENTA) Share Price Crosses Below Two Hundred Day Moving Average - Time to Sell?February 28, 2025 | marketbeat.comEnanta Pharmaceuticals (NASDAQ:ENTA) Upgraded to "Hold" at StockNews.comStockNews.com raised shares of Enanta Pharmaceuticals from a "sell" rating to a "hold" rating in a research note on Wednesday.February 19, 2025 | marketbeat.comEnanta Pharmaceuticals' SWOT analysis: RSV and immunology drive stock outlookFebruary 17, 2025 | msn.comWith Enanta Pharmaceuticals Up 46%, Insider Buyers Count Their ReturnsFebruary 15, 2025 | finance.yahoo.comPresident of Enanta Pharmaceuticals Picks Up 5.9% More StockFebruary 15, 2025 | finance.yahoo.comEnanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Given Average Rating of "Moderate Buy" by AnalystsEnanta Pharmaceuticals, Inc. (NASDAQ:ENTA - Get Free Report) has been given a consensus rating of "Moderate Buy" by the five ratings firms that are currently covering the firm, MarketBeat Ratings reports. One analyst has rated the stock with a sell recommendation, three have given a buy recommendaFebruary 14, 2025 | marketbeat.comEnanta Pharmaceuticals CEO Luly Jay R. buys $256,050 in common stockFebruary 13, 2025 | msn.comEnanta Pharmaceuticals (ENTA) Receives a Buy from Evercore ISIFebruary 13, 2025 | markets.businessinsider.comHC Wainwright Issues Pessimistic Estimate for ENTA EarningsEnanta Pharmaceuticals, Inc. (NASDAQ:ENTA - Free Report) - Equities researchers at HC Wainwright decreased their Q2 2025 earnings per share (EPS) estimates for shares of Enanta Pharmaceuticals in a research note issued to investors on Tuesday, February 11th. HC Wainwright analyst E. Arce now antiFebruary 13, 2025 | marketbeat.comEnanta Pharmaceuticals, Inc. (NASDAQ:ENTA) CEO Buys $256,050.00 in StockFebruary 13, 2025 | insidertrades.comJay R. Luly Purchases 45,000 Shares of Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) StockEnanta Pharmaceuticals, Inc. (NASDAQ:ENTA - Get Free Report) CEO Jay R. Luly bought 45,000 shares of the firm's stock in a transaction dated Wednesday, February 12th. The stock was acquired at an average cost of $5.69 per share, with a total value of $256,050.00. Following the transaction, the chief executive officer now owns 846,638 shares of the company's stock, valued at $4,817,370.22. This trade represents a 5.61 % increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which can be accessed through this hyperlink.February 12, 2025 | marketbeat.comEnanta Pharmaceuticals (NASDAQ:ENTA) Rating Lowered to Sell at StockNews.comStockNews.com downgraded Enanta Pharmaceuticals from a "hold" rating to a "sell" rating in a report on Tuesday.February 11, 2025 | marketbeat.comJMP Securities Reaffirms "Market Outperform" Rating for Enanta Pharmaceuticals (NASDAQ:ENTA)JMP Securities restated a "market outperform" rating and issued a $21.00 price target on shares of Enanta Pharmaceuticals in a research note on Tuesday.February 11, 2025 | marketbeat.comEnanta reports Q1 EPS ($1.05), consensus ($1.35)February 11, 2025 | markets.businessinsider.comJMP Securities maintains Enanta stock with $21 targetFebruary 11, 2025 | msn.comHC Wainwright maintains $18 target on Enanta shares, affirms BuyFebruary 11, 2025 | msn.comHC Wainwright Reiterates Buy Rating for Enanta Pharmaceuticals (NASDAQ:ENTA)HC Wainwright reiterated a "buy" rating and issued a $18.00 price objective on shares of Enanta Pharmaceuticals in a research note on Tuesday.February 11, 2025 | marketbeat.comEnanta Pharmaceuticals (NASDAQ:ENTA) Posts Quarterly Earnings Results, Beats Expectations By $0.11 EPSEnanta Pharmaceuticals (NASDAQ:ENTA - Get Free Report) announced its quarterly earnings results on Monday. The biotechnology company reported ($1.05) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.16) by $0.11. Enanta Pharmaceuticals had a negative return on equity of 73.02% and a negative net margin of 171.57%.February 10, 2025 | marketbeat.comEnanta Pharmaceuticals Reports Financial Results for its Fiscal First Quarter Ended December 31, 2024February 10, 2025 | businesswire.comEnanta Pharmaceuticals (ENTA) Expected to Announce Quarterly Earnings on WednesdayEnanta Pharmaceuticals (NASDAQ:ENTA) will be releasing earnings before the market opens on Wednesday, February 5, Financial Modeling Prep reports.January 29, 2025 | marketbeat.comAssenagon Asset Management S.A. Raises Stock Holdings in Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA)Assenagon Asset Management S.A. lifted its stake in Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA - Free Report) by 34.1% during the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 192,856 shares of the biotechnology company's stock aftJanuary 25, 2025 | marketbeat.comJPMorgan Chase & Co. Increases Stock Position in Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA)JPMorgan Chase & Co. grew its stake in Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA - Free Report) by 53.7% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 243,628 shares of the biotechnolJanuary 21, 2025 | marketbeat.comEnanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Given Consensus Rating of "Moderate Buy" by BrokeragesShares of Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA - Get Free Report) have been assigned a consensus recommendation of "Moderate Buy" from the five research firms that are currently covering the company, MarketBeat reports. One equities research analyst has rated the stock with a sell recommendatJanuary 20, 2025 | marketbeat.com Get Enanta Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for ENTA and its competitors with MarketBeat's FREE daily newsletter. Email Address ENTA Media Mentions By Week ENTA Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. ENTA News Sentiment▼1.550.75▲Average Medical News Sentiment ENTA News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. ENTA Articles This Week▼42▲ENTA Articles Average Week Get Enanta Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for ENTA and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies RLAY News Today RGNX News Today ZVRA News Today UPB News Today AMLX News Today ARVN News Today DNA News Today CGEM News Today ALT News Today SEPN News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:ENTA) was last updated on 5/25/2025 by MarketBeat.com Staff From Our PartnersGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredBuffett’s favorite chart just hit 209% – here’s what that means for goldA Historic Gold Announcement Is About to Rock Wall Street For months, sharp-eyed analysts have watched the ...Golden Portfolio | SponsoredIs President Trump Lying To You With This?President Trump’s economic transition isn’t without hardship. But what if there were a smart, tax-free way to ...Colonial Metals | SponsoredA grave, grave error.I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredTrump’s Bitcoin Reserve is No Accident…Bitcoin's supply is being drained at unprecedented rates, but while most investors focus solely on Bitcoin, th...Crypto 101 Media | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredMassive new energy source found in UtahNEW THIS WEEK: Huge Energy Discovery In Utah The Department of Energy say it could power America for millio...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Enanta Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Enanta Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy ENTA Stock Free ENTA Stock Alerts